The importance of glycemic control: How low should we go with HbA1c? Start early, go safe, go low

Journal of Diabetes and its Complications

Volumn 25, Issue 3, 2011, Pages 202-207

  Benhalima, Katrien ^a   Standl, Eberhard ^b   Mathieu, Chantal ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cardiovascular complications; Diabetes; HbA1c; Hypoglycemia; Microvascular complications

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; EXENDIN 4; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INSULIN DERIVATIVE; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFE EXPECTANCY; LONG TERM CARE; MICROALBUMINURIA; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION;

EID: 79955060728     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2010.03.002     Document Type: Review

References (24)

1. Abraira C. Veterans Affairs Diabetes Trial: background, design, risk factor control, glycemic separation, and hypoglycemia Presented at: American Diabetes Association-68th Annual Scientific Sessions; June 6-11, 2008 San Francisco, CA
2. Cukierman-Yaffe T., Gerstein H.C., Williamson J.D., Lazar R.M., Lovato L., Miller M.E., Coker L.H., Murray A., Sullivan M.D., Marcovina S.M., Launer L.J. for the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators Relationship between baseline glycemic control and cognitive function in individuals with Type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial Diabetes Care 32 2 2009 221 226
3. Currie C.J., Peters J.R., Tynan A., Evans M., Heine R.J., Bracco O.L., Zagar T., and Poole C.D. Survival as a function of HbA1c in people with Type 2 diabetes: a retrospective cohort study Lancet 375 2010 481 489
4. Del Prato S. Megatrials in Type 2 diabetes. From excitement to frustration? Diabetologia 52 7 2009 1219 1226
5. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., Zieve F.J., Marks J., Davis S.N., Hayward R., Warren S.R., Goldman S., McCarren M., Vitek M.E., Henderson W.G., Huang G.D. for the VADT Investigators Glucose control and vascular complications in veterans with Type 2 diabetes New England Journal of Medicine 360 2 2009 129 139
6. Ewing D.J., Boland O., Neilson J.M.M., Cho C.G., and Clarke B.F. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients Diabetologia 34 3 1991 182 185
7. Gæde P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes New England Journal of Medicine 358 6 2008 580 591 (Pubitemid 351214285)
8. Gæde P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes New England Journal of Medicine 348 5 2003 383 393 (Pubitemid 36159355)
9. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil H.A.W. 10-year follow-up of intensive glucose control in Type 2 diabetes New England Journal of Medicine 359 15 2008 1577 1589
10. Khaw K.T., Wareham N., Bingham S., Luben R., Welch A., and Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk Annals of Internal Medicine 141 6 2004 413 420
11. Krzentowski G., Zhang L., Albert A., and Lefèbvre P. Another look at the implications of the DCCT study Annals of Endocrinology (Paris) 65 5 2004 429 435 (Pubitemid 39557017)
12. Lebovitz H.E. Glycaemic control and vascular complications in Type 2 diabetes: new observations and clinical significance Journal of the Indian Medical Association 106 11 2008 724 726
13. Mannucci E., Monami M., Lamanna C., Gori F., and Marchionni N. Prevention of cardiovascular disease through glycemic control in Type 2 diabetes: A meta-analysis of randomized clinical trials Nutrition, Metabolism, and Cardiovascular Disease 19 9 2009 604 612
14. Ray K.K., Seshasai S.R.K., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., Erqou S., and Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials The Lancet 373 9677 2009 1765 1772
15. Standl E., Muller M., and Schnell O. The impact of glucose-lowering therapy on cardiovascular outcomes Best Practice and Research: Clinical Endocrinology and Metabolism 23 3 2009 401 411
16. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., and Holman R.R. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study British Medical Journal 321 7258 2000 405 412 (Pubitemid 30609442)
17. Tattersall R.B., and Gill G.V. Unexplained deaths of Type 1 diabetic patients Diabetic Medicine 8 1 1991 49 58
18. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in Type 2 diabetes New England Journal of Medicine 358 24 2008 2545 2559
19. The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes New England Journal of Medicine 358 24 2008 2560 2572
20. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes New England Journal of Medicine 353 25 2005 2643 2653
21. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus New England Journal of Medicine 329 14 1993 977 986
22. The Diabetes Control and Complications Trial Research Group The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial Diabetes 45 10 1996 1289 1298
23. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34) The Lancet 352 9131 1998 854 865
24. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33) The Lancet 352 9131 1998 837 853